Abstract 3387
Background
Patients undergoing haematopoietic stem cell transplantation (HSCT) are often hospitalised in protective isolation in order to reduce the risk of dangerous infection. However, they could experience isolation-related suffering, problems in relationships with others, and difficulties in relating to themselves. Oncology nurses might play an important role in mitigating perceived isolation and in providing emotional support. The aim of this study was to identify which factors can influence the level of emotional support from nurses perceived by patients with haematological malignancies undergoing HSCT in isolation.
Methods
A multicentre prospective study was conducted in 10 haematology centres of the Italian Group of stem cell transplant (GITMO). Emotional support from nurses was measured between day +7 and +9 post-transplant using the Scale Experiences on the Newcastle Satisfaction with Nurses Scale. Multiple linear regression analysis was performed.
Results
The participants were 186 adult patients receiving autologous (48%) or allogeneic (52%) HSCT in protective isolation. They were mainly male (61.6%) with a mean age of 50.1 (SD = 13.4; range=19-71). The regression model explained 23% of the total variance (p < .001) (Table). Sex, pain level, double room, satisfaction with information received before HSCT, and patients to nurse ratio were independently associated with emotional support from nurses.Table: CN56
Regression model predicting perceived emotional support from nurses (n = 186)
β | 95% CI | P | |
---|---|---|---|
Sex (female) | .193 | (.056; .332) | .006 |
Pain level | -.147 | (-.287; -.007) | .040 |
First HSCT | .099 | (-.038; .234) | .158 |
Double room | .242 | (.098; .378) | .001 |
Satisfaction with info | .403 | (.264; .547) | <.001 |
Patients to nurse | -.168 | (-.316; -.027) | .021 |
P | <.001 |
Conclusions
Patients who reported high emotional support from nurses were female, with low pain, satisfied with information received, and hospitalised in double room in a ward with a low patients to nurse ratio. It is crucial to reduce the patients to nurse ratio in order to promote the role of nurses in providing emotional support.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Campus Bio-Medico di Roma University.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
4370 - Continental differences in pathologic response with neoadjuvant ipilimumab (IPI) plus nivolumab (NIVO) in patients with macroscopic stage III melanoma in the phase 2 OpACIN-neo trial.
Presenter: Irene Reijers
Session: Poster Display session 3
Resources:
Abstract
3230 - Comparable responses of melanoma at primary site and synchronous lymph node metastases upon neoadjuvant ipilimumab (IPI) and nivolumab (NIVO)
Presenter: Judith Versluis
Session: Poster Display session 3
Resources:
Abstract
3171 - Adjuvant Therapies for Stage III Melanoma: Benchmarks for Bringing Clinical Trials to Clinical Practice
Presenter: Tina HIEKEN
Session: Poster Display session 3
Resources:
Abstract
3493 - Mixture-cure modeling for resected stage III/IV melanoma in the phase 3 CheckMate 238 trial
Presenter: Jeffrey Weber
Session: Poster Display session 3
Resources:
Abstract
3036 - An open-label, non-randomized, phase IIIb study of trametinib in combination with dabrafenib for patients with unresectable advanced BRAFV600-mutant melanoma: a subgroup analysis of patients with brain metastasis
Presenter: Caroline Dutriaux
Session: Poster Display session 3
Resources:
Abstract
2233 - Adverse event (AE) kinetics in patients (pts) treated with dabrafenib + trametinib (D + T) in the metastatic and adjuvant setting
Presenter: Jean Jacques Grob
Session: Poster Display session 3
Resources:
Abstract
2435 - A Single Arm, Open Label, Phase II, Multicenter Study to Assess the Detection of the BRAF V600 Mutation on cfDNA from Plasma in Patients with Advanced Melanoma
Presenter: Piotr Rutkowski
Session: Poster Display session 3
Resources:
Abstract
1766 - Efficacy and Safety of Dabrafenib and Trametinib in Patients with Metastatic BRAFV600 Mutation-positive Melanoma in the Real-World Setting – Interim results of the non-interventional COMBI-r study
Presenter: Carola Berking
Session: Poster Display session 3
Resources:
Abstract
2131 - Trial update: A randomized Phase Ib/II study of the selective small molecule Axl inhibitor Bemcentinib (BGB324) in combination with either dabrafenib/trametinib (D/T) or pembrolizumab in patients with metastatic melanoma
Presenter: Oddbjørn Straume
Session: Poster Display session 3
Resources:
Abstract
4074 - Analysis of pyrexia in patients (pts) treated with dabrafenib (D) and/or trametinib (T) across clinical trials
Presenter: Caroline Robert
Session: Poster Display session 3
Resources:
Abstract